Clinical outcomes after first-line EGFR inhibitor treatment for patients with NSCLC, EGFR mutation, and poor performance status

Area of Science:

• Oncology
• Pharmacology

Background:

• Gefitinib showed activity in advanced non-small cell lung cancer (NSCLC) patients, including those with poor performance status (PS).
• Efficacy of gefitinib may be limited in patients with EGFR mutations and poor PS compared to those with good PS.
• This study retrospectively analyzed gefitinib outcomes in advanced NSCLC patients with EGFR mutations and poor PS.

Purpose of the Study:

• To retrospectively investigate the clinical outcomes of gefitinib treatment in advanced NSCLC patients with EGFR mutations and poor performance status.
• To evaluate the efficacy and safety of gefitinib in a specific subgroup of NSCLC patients.

Main Methods:

• Retrospective evaluation of 208 advanced NSCLC patients treated with gefitinib (2004-2013).
• Outcomes analyzed after stratification by gender, smoking status, histological subtype, and EGFR mutation status.
• Multivariate analysis was performed to identify independent prognostic factors.

Main Results:

• Fifty-two patients (25.0%) with advanced NSCLC, EGFR mutation, and poor PS received gefitinib.
• Overall response rate was 65.4%, with median progression-free survival of 6.6 months and median survival of 19.6 months.
• A PS of 4 was independently associated with poor outcomes (HR=10.5; p=0.0091), and interstitial lung disease caused death in 11.5% of patients.

Conclusions:

• Patients with advanced NSCLC, EGFR mutation, and poor PS exhibit poor outcomes with gefitinib.
• Despite poor outcomes, gefitinib indication remains unchanged, but requires careful follow-up due to increased toxicity in poor PS patients.
• Oncologists should exercise caution and provide closer monitoring for this patient group.